-
Subject Areas on Research
-
1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas.
-
3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging.
-
4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
-
A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis.
-
A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma.
-
A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo.
-
A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.
-
A comparative study of brain tumor cells from different age and anatomical locations using 3D biomimetic hydrogels.
-
A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.
-
A fully automated artificial intelligence method for non-invasive, imaging-based identification of genetic alterations in glioblastomas.
-
A fully automatic extraction of magnetic resonance image features in glioblastoma patients.
-
A genetic variant in the APE1/Ref-1 gene promoter -141T/G may modulate risk of glioblastoma in a Chinese Han population.
-
A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion.
-
A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma.
-
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
-
A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression.
-
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
-
A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.
-
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
-
A pooled multisite analysis of the effects of atopic medical conditions in glioma risk in different ethnic groups.
-
A promising cancer vaccine.
-
A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme.
-
A public database for gene expression in human cancers.
-
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
-
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.
-
A review of glioblastoma immunotherapy.
-
A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.
-
ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.
-
ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.
-
AJAP1 expression modulates glioma cell motility and correlates with tumor growth and survival.
-
Aberrant NF-kappaB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factor.
-
Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas.
-
Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice.
-
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.
-
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.
-
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
-
Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.
-
Adult atypical teratoid/rhabdoid tumor (AT/RT): A case of mistaken identity.
-
Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
-
Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age.
-
Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study.
-
Alternating Electric Fields for the Treatment of Glioblastoma.
-
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.
-
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.
-
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.
-
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
-
An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab.
-
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
-
An integrated genomic analysis of human glioblastoma multiforme.
-
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.
-
Anaplastic human gliomas grown in athymic mice. Morphology and glial fibrillary acidic protein expression.
-
Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma.
-
Anti-angiogenic therapy for high-grade glioma.
-
Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
-
Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer.
-
Antiangiogenic therapy for high-grade glioma.
-
Antigenic heterogeneity of human anaplastic gliomas and glioma-derived cell lines defined by monoclonal antibodies.
-
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
-
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.
-
Aryl Hydrocarbon Receptor Signaling Controls CD155 Expression on Macrophages and Mediates Tumor Immunosuppression.
-
Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.
-
Association between body mass index and mortality in patients with glioblastoma mutliforme.
-
Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
-
Association of sequence variants on chromosomes 20, 11, and 5 (20q13.33, 11q23.3, and 5p15.33) with glioma susceptibility in a Chinese population.
-
Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme.
-
Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking.
-
Avastin: more questions than answers. .
-
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
-
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
-
Bayesian genome- and epigenome-wide association studies with gene level dependence.
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
-
Bevacizumab and daily temozolomide for recurrent glioblastoma.
-
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
-
Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.
-
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
-
Bevacizumab therapy for glioblastoma: a passionate discussion.
-
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
-
Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL.
-
Biology of gliomas: potential clinical implications of glioma cellular heterogeneity.
-
Brain tumor types induced by the Schmidt-Ruppin strain of Rous sarcoma virus in inbred Fischer rats.
-
CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.
-
CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
-
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.
-
CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
-
Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.
-
Caregiver burden by treatment and clinical characteristics of patients with glioblastoma.
-
Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
-
Caspase 8 is absent or low in many ex vivo gliomas.
-
Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.
-
Characterization of new gangliosides of the lactotetraose series in murine xenografts of a human glioma cell line.
-
Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.
-
Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.
-
Chemopotentiation by ultrafractionated radiotherapy in glioblastoma resistant to conventional therapy.
-
Chromosomal characteristics of childhood brain tumors.
-
Chromosomal evolution in malignant human gliomas starts with specific and usually numerical deviations.
-
Chromosome breakpoint at 17q11.2 and insertion of DNA from three different chromosomes in a glioblastoma with exceptional glial fibrillary acidic protein expression.
-
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
-
Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro.
-
Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.
-
Clinical applications of a peptide-based vaccine for glioblastoma.
-
Clinical characteristics and treatment of malignant brainstem gliomas in elderly patients.
-
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
-
Clinicopathological characteristics and treatment of rhabdoid glioblastoma.
-
Cold Plasma Discharge Tube Enhances Antitumoral Efficacy of Temozolomide.
-
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.
-
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
-
Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?
-
Commentary: Laser Interstitial Thermal Therapy for First-Line Treatment of Surgically Accessible Recurrent Glioblastoma: Outcomes Compared With a Surgical Cohort.
-
Comparative genetic patterns of glioblastoma multiforme: potential diagnostic tool for tumor classification.
-
Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.
-
Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging.
-
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
-
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
-
Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma.
-
Computer-extracted MR imaging features are associated with survival in glioblastoma patients.
-
Computerized assessment of vessel morphological changes during treatment of glioblastoma multiforme: report of a case imaged serially by MRA over four years.
-
Constrained customization of non-coplanar beam orientations in radiotherapy of brain tumours.
-
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
-
Conventional external beam radiotherapy for central nervous system malignancies.
-
Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
-
Cortical localization of temporal lobe language sites in patients with gliomas.
-
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
-
Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.
-
Crizotinib and erlotinib inhibits growth of c-Met+/EGFRvIII+ primary human glioblastoma xenografts.
-
Cryopreservation of neurospheres derived from human glioblastoma multiforme.
-
Cytostatic hypothermia and its impact on glioblastoma and survival.
-
Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus.
-
DNA interstrand crosslinking and strand break repair in human glioma cell lines of varying [1,3-bis(2-chloroethyl)-1-nitrosourea] resistance.
-
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
-
Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vitro reaction with glutathione.
-
Deletion of p16 and p15 genes in brain tumors.
-
Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma.
-
Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.
-
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.
-
Detection of DNA damage in transcriptionally active genes by RT-PCR and assessment of repair of cisplatin-induced damage in the glutathione S-transferase-pi gene in human glioblastoma cells.
-
Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
-
Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination.
-
Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.
-
Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.
-
Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells.
-
Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas.
-
Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.
-
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
-
Distinctive effects of the cellular inhibitor of apoptosis protein c-IAP2 through stabilization by XIAP in glioblastoma multiforme cells.
-
Distress persists in long-term brain tumor survivors with glioblastoma multiforme.
-
Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
-
Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells.
-
Dual-mode IVUS transducer for image-guided brain therapy: preliminary experiments.
-
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
-
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.
-
EGF mutant receptor vIII as a molecular target in cancer therapy.
-
EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.
-
EGFR mutations and sensitivity to gefitinib.
-
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
-
EGFRvIII as a promising target for antibody-based brain tumor therapy.
-
EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
-
EGFRvIII-targeted vaccination therapy of malignant glioma.
-
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
-
Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial".
-
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
-
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
-
Effect of cisplatin and BCNU on MMP-2 levels in human glioblastoma cell lines in vitro.
-
Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study.
-
Electrotaxis of Glioblastoma and Medulloblastoma Spheroidal Aggregates.
-
Emerging immunotherapies for glioblastoma.
-
Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.
-
Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At.
-
Engineering Controlled Peritumoral Inflammation to Constrain Brain Tumor Growth.
-
Engineering challenges for brain tumor immunotherapy
-
Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
-
Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
-
Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
-
EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase.
-
Epidemiologic and molecular prognostic review of glioblastoma.
-
Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors.
-
Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay.
-
Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.
-
Evaluation of pre-radiotherapy cyclophosphamide in patients with newly diagnosed glioblastoma multiforme. Writing Committee for The Brain Tumor Center at Duke.
-
Evaluation of software for registration of contrast-enhanced brain MR images in patients with glioblastoma multiforme.
-
Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction.
-
Exomic sequencing of four rare central nervous system tumor types.
-
Extraneural Glioblastoma Multiforme Vertebral Metastasis.
-
Federated learning enables big data for rare cancer boundary detection.
-
Females have the survival advantage in glioblastoma.
-
First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma.
-
First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800.
-
Flow Cytometric Identification of Tumor-Infiltrating Lymphocytes from Glioblastoma.
-
For whom the T cells troll? Bispecific T-cell engagers in glioblastoma.
-
GBM radiosensitizers: dead in the water…or just the beginning?
-
GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma.
-
Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.
-
Gene expression profiling and genetic markers in glioblastoma survival.
-
Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.
-
Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.
-
Genome-wide methylation analyses in glioblastoma multiforme.
-
Genomic alterations and the pathogenesis of glioblastoma.
-
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
-
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.
-
Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.
-
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
-
Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995-2015.
-
Glioblastoma multiforme and the epidermal growth factor receptor.
-
Glioblastoma multiforme with small cell neuronal-like component: association with human neurotropic JC virus.
-
Glioblastoma multiforme: a review of therapeutic targets.
-
Glioblastoma multiforme: a review of where we have been and where we are going.
-
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
-
Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress.
-
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth.
-
Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells.
-
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
-
Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor.
-
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
-
Gradient hydrogels for screening stiffness effects on patient-derived glioblastoma xenograft cellfates in 3D.
-
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
-
Guiding intracortical brain tumour cells to an extracortical cytotoxic hydrogel using aligned polymeric nanofibres.
-
HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.
-
Ham56-immunoreactive macrophages in untreated infiltrating gliomas.
-
High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.
-
High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor.
-
How heterogeneous are gliomas?
-
How much is enough? The question of extent of resection in glioblastoma multiforme.
-
Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA.
-
Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.
-
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.
-
IDH1 and IDH2 mutations in gliomas.
-
IDH3α regulates one-carbon metabolism in glioblastoma.
-
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).
-
Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme.
-
Identifying new small molecule anti-invasive compounds for glioma treatment.
-
Identifying potential tumor markers and antigens by database mining and rapid expression screening.
-
Imaging descriptors improve the predictive power of survival models for glioblastoma patients.
-
Imaging of convection enhanced delivery of toxins in humans.
-
Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma.
-
Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients.
-
Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma.
-
Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations.
-
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
-
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
-
Immunomodulation for glioblastoma.
-
Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity.
-
Immunotherapy advances for glioblastoma.
-
Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?
-
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
-
Immunotherapy for primary brain tumors: no longer a matter of privilege.
-
Immunotherapy with tumor vaccines for the treatment of malignant gliomas.
-
In vitro repair synthesis of BCNU-induced DNA damage.
-
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
-
Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.
-
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
-
Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue.
-
Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas.
-
Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide.
-
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
-
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
-
Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.
-
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes.
-
Integrated genomic analysis of survival outliers in glioblastoma.
-
Integrin alpha 6 regulates glioblastoma stem cells.
-
Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study.
-
Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
-
Intraoperative dynamic MRI: localization of sites of brain tumor recurrence after high-dose radiotherapy.
-
Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.
-
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
-
Is There a Role for Immunotherapy in Central Nervous System Cancers?
-
Is cytomegalovirus a therapeutic target in glioblastoma?
-
Is the long-term survival of patients with intracranial glioblastoma multiforme overstated?
-
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.
-
Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
-
Isocitrate dehydrogenase mutations in gliomas.
-
Label-free oxygen-metabolic photoacoustic microscopy in vivo.
-
Laminin alpha 2 enables glioblastoma stem cell growth.
-
Leveraging external data in the design and analysis of clinical trials in neuro-oncology.
-
Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors.
-
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
-
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
-
Loss of heterozygosity for 10q loci in human gliomas.
-
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
-
MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus.
-
MR image-guided portal verification for brain treatment field.
-
MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences.
-
MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set.
-
MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and surgical resection specimen.
-
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
-
MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
-
MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.
-
MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization.
-
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
-
Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
-
Malignant supratentorial ganglioglioma (ganglion cell-giant cell glioblastoma): a case report and review of the literature.
-
Malignant supratentorial glial-neuronal neoplasms: report of two cases and review of the literature.
-
Management of GBM: a problem of local recurrence.
-
Management of glioblastoma in elderly patients.
-
Management of glioblastoma: State of the art and future directions.
-
Management of glioblastoma: an Australian perspective.
-
Matrix Stiffness Modulates Patient-Derived Glioblastoma Cell Fates in Three-Dimensional Hydrogels.
-
Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo.
-
Met and hepatocyte growth factor/scatter factor expression in human gliomas.
-
Metabolomic profiling of sphingolipids in human glioma cell lines by liquid chromatography tandem mass spectrometry.
-
Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma.
-
Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.
-
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
-
Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma.
-
Mimicking brain tumor-vasculature microanatomical architecture via co-culture of brain tumor and endothelial cells in 3D hydrogels.
-
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
-
Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.
-
Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.
-
Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.
-
Molecular pathogenesis of malignant gliomas.
-
Monitoring radiographic brain tumor progression.
-
Monoclonal antibodies for brain tumour treatment.
-
Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration.
-
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
-
Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.
-
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.
-
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.
-
Mutant metabolic enzymes are at the origin of gliomas.
-
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
-
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
-
N-acetyl-L-aspartic acid content of human neural tumours and bovine peripheral nervous tissues.
-
NDRG4 is required for cell cycle progression and survival in glioblastoma cells.
-
Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery.
-
Neural G0: a quiescent-like state found in neuroepithelial-derived cells and glioma.
-
Neuro-oncology: Glioblastoma--community adjusts to new standard of care.
-
Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?
-
Neuro-oncology: unmasking the multiforme in glioblastoma.
-
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
-
Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma.
-
Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.
-
New Approaches to Glioblastoma.
-
New Directions in the Treatment of Glioblastoma.
-
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
-
Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab.
-
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.
-
Notch promotes radioresistance of glioma stem cells.
-
Nucleus-Translocated ACSS2 Promotes Gene Transcription for Lysosomal Biogenesis and Autophagy.
-
Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.
-
Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.
-
Our failure to advance new treatments for glioma to market.
-
Outcome and prognostic factors in adult cerebellar glioblastoma.
-
Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study.
-
Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma.
-
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
-
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
-
PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression.
-
Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness.
-
Pediatric brain stem tumors: patterns of treatment failure and their implications for radiotherapy.
-
Peptide vaccines for the treatment of glioblastoma.
-
Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth.
-
Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach.
-
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
-
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
-
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
-
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.
-
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
-
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
-
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
-
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.
-
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
-
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.
-
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
-
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
-
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
-
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
-
Phase II study of Dovitinib in recurrent glioblastoma.
-
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
-
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.
-
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
-
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
-
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
-
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
-
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
-
Phase II trial of gefitinib in recurrent glioblastoma.
-
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
-
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
-
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
-
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
-
Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory.
-
Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome.
-
Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme.
-
Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.
-
Prevalence of autoimmunity and atopy in US adults with glioblastoma and meningioma.
-
Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.
-
Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers.
-
Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas.
-
Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
-
Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma.
-
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.
-
Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide.
-
Promising vaccines for treating glioblastoma.
-
Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
-
Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors.
-
Prospect of rindopepimut in the treatment of glioblastoma.
-
Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors.
-
Prospects of immune checkpoint modulators in the treatment of glioblastoma.
-
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
-
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy.
-
Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
-
Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial.
-
Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US.
-
Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.
-
Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations.
-
Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+.
-
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
-
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
-
Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators.
-
Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.
-
Recombinant Poliovirus for Cancer Immunotherapy.
-
Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.
-
Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.
-
Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype.
-
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.
-
Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.
-
Recurrent Glioblastoma Treated with Recombinant Poliovirus.
-
Recurrent glioblastoma diagnosed by fluorescence in situ hybridization for EGFR.
-
Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP(5+), Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma Multiforme.
-
Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene.
-
Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
-
Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition.
-
Regulatory T cells move in when gliomas say "I Do".
-
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
-
Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods.
-
Repeatability of Automated Image Segmentation with BraTumIA in Patients with Recurrent Glioblastoma.
-
Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma.
-
Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme.
-
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
-
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
-
Reversing the Warburg effect as a treatment for glioblastoma.
-
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
-
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
-
Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
-
Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations.
-
Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study.
-
Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model.
-
SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies.
-
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.
-
Sample type bias in the analysis of cancer genomes.
-
Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
-
Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion.
-
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.
-
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.
-
Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.
-
Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.
-
Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta.
-
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.
-
Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival.
-
Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
-
Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours.
-
Speckle modulation enables high-resolution wide-field human brain tumor margin detection and in vivo murine neuroimaging.
-
Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.
-
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.
-
Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.
-
Stereotactic radiosurgery for recurrent malignant gliomas.
-
Structure of the human allelic glutathione S-transferase-pi gene variant, hGSTP1 C, cloned from a glioblastoma multiforme cell line.
-
Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
-
Survival after reoperation for recurrent glioblastoma.
-
Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation.
-
Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study.
-
Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
-
Synthesis and preliminary evaluation of n.c.a. iodoquine: a novel radiotracer with high uptake in cells with high ALDH1 expression.
-
T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma.
-
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
-
T-cell Dysfunction in Glioblastoma: Applying a New Framework.
-
Targeted genomic CRISPR-Cas9 screen identifies MAP4K4 as essential for glioblastoma invasion.
-
Targeted radiotherapy for malignant gliomas.
-
Targeted radiotherapy of brain tumours.
-
Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus.
-
Targeting A20 decreases glioma stem cell survival and tumor growth.
-
Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.
-
Targeting UDP-α-D-glucose 6-dehydrogenase inhibits glioblastoma growth and migration.
-
Temozolomide and treatment of malignant glioma.
-
Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.
-
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
-
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.
-
The Effects of Thermal Preconditioning on Oncogenic and Intraspinal Cord Growth Features of Human Glioma Cells.
-
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
-
The Safety of available immunotherapy for the treatment of glioblastoma.
-
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
-
The biology of malignant gliomas--a comprehensive survey.
-
The current state of immunotherapy for gliomas: an eye toward the future.
-
The fallacy of single-agent chemotherapy for cancer.
-
The fallacy of the localized supratentorial malignant glioma.
-
The fine structure of canine gliomas and intracranial sarcomas induced by the Schmidt-Ruppin strain of the Rous sarcoma virus.
-
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
-
The glioblastoma multiforme in Georgia, 1977-1981.
-
The human glutathione S-transferase P1 protein is phosphorylated and its metabolic function enhanced by the Ser/Thr protein kinases, cAMP-dependent protein kinase and protein kinase C, in glioblastoma cells.
-
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.
-
The in vitro radiosensitization of human glioblastoma with pentoxifylline.
-
The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly.
-
The integrated landscape of driver genomic alterations in glioblastoma.
-
The radiosurgery fractionation quandary: single fraction or hypofractionation?
-
The somatic genomic landscape of glioblastoma.
-
The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells.
-
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.
-
Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.
-
Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming.
-
Total dietary antioxidant index and survival in patients with glioblastoma multiforme.
-
Transcriptional response to hypoxia in human tumors.
-
Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle.
-
Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin.
-
Treatment of newly diagnosed glioblastoma multiforme.
-
Treatment of radiation-induced nervous system injury with heparin and warfarin.
-
Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
-
Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients.
-
Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class.
-
Twenty-year survival in glioblastoma: a case report and molecular profile.
-
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank.
-
Upfront Magnetic Resonance Imaging-Guided Stereotactic Laser-Ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched Cohort of Biopsy-Only Patients.
-
Use of bevacizumab in recurrent glioblastoma.
-
Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation.
-
Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
-
Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.
-
Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.
-
Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows.
-
Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.
-
Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.
-
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
-
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
-
XRCC3 haplotypes and risk of gliomas in a Chinese population: a hospital-based case-control study.
-
miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways.
-
Keywords of People
-
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology
-
Sampson, John Howard,
Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine,
Biomedical Engineering
-
Yan, Hai,
Adjunct Professor of Pathology,
Pathology